Research and Publications

This landmark review organised ageing into a clear set of core biological processes (for example DNA damage, loss of cellular repair, and chronic inflammation). It gave scientists and clinicians a shared “map” of what drives ageing—still used today to structure longevity testing, interventions, and research priorities.

This paper made the case that ageing itself is the biggest risk factor for many long-term conditions and that targeting ageing mechanisms could improve “healthspan” (years lived in good health). It helped mainstream the idea that longevity medicine is not about one disease, but about shifting overall risk across many diseases at once

In a rigorous multi-site mouse study, an mTOR-inhibiting drug (rapamycin) extended lifespan even when started later in life. It was a major proof-point that medicines can modify fundamental ageing biology in mammals, helping catalyse today’s “geroprotective” drug research

Senescent (“zombie”) cells accumulate with age and can drive inflammation and tissue dysfunction. This study showed that selectively removing these cells in mice delayed several ageing-related problems, helping establish cellular senescence as a central target in longevity medicine.

Building on the senescence concept, this paper tested “senolytic” drugs designed to reduce senescent cell burden. In old mice, treatment improved physical function and increased remaining lifespan, accelerating real-world interest in senolytics and their careful clinical translation

This study introduced a method to estimate biological age from DNA methylation patterns across many human tissues. It helped move longevity from theory to measurement and enabled research (and later clinical programmes) to track whether biology looks “older” or “younger” than the calendar age.

GrimAge is an epigenetic clock designed to predict lifespan and time to age-related disease more strongly than earlier clocks. It helped set a higher bar for longevity testing: the best measures should meaningfully forecast health outcomes, not just estimate age.

This paper helped bring longevity medicine toward practical clinical trials by arguing for repurposing a well-known drug (metformin) to target ageing-related biology and multiple diseases together. It also helped legitimise the concept of testing “anti-ageing” approaches using mainstream medical trial methods and endpoints.

This large review showed that people who follow several healthy lifestyle habits at once - such as being physically active, eating well, maintaining a healthy weight, and not smoking - live significantly longer than those who do not. Importantly, the benefits increase step-by-step with each additional healthy habit, showing that small changes can add up to meaningful gains in longevity.

This influential review found that people who walk more each day live longer, with benefits seen well below the often-quoted 10,000-step target. The findings helped shift the conversation toward realistic, achievable movement goals that still deliver significant longevity benefits.

Rather than single foods or nutrients, this review examined overall dietary patterns and found that higher-quality diets are consistently linked to lower risk of death. It helped move nutrition science away from fads and toward sustainable, whole-diet approaches for long-term health.

This landmark review showed that both short and excessively long sleep durations are associated with higher risk of early death. It helped establish sleep as a core pillar of long-term health, alongside diet and physical activity.

This review showed that long-term physiological stress—measured as “allostatic load”—is strongly associated with increased mortality risk. It provided biological evidence that chronic stress literally accelerates wear and tear on the body over time.